Crowd of KOLs and DOLs

DOLs: A New Frontier

Whether you call them Key Opinion Leaders (KOLs) or Key External Experts (KEEs), success in the pharmaceutical space has always started with one essential task: identifying the right experts to engage, influence, and collaborate with. These are the clinicians who publish groundbreaking research, present at major conferences, and serve on Read more

By Jason Shaneyfelt, ago
Scientist in googles

Industry Happenings – October 2026

Learn how major industry trends are influencing the future of biopharma, including patent expiration challenges, evolving regulatory pathways, and emerging therapeutic targets that are attracting significant investment and attention. Source: PharmaVoice A wave of patent expirations is expected to put more than $500 billion in global prescription drug sales at Read more

By Jason Shaneyfelt, ago
Magnifying glass inspecting men in suits

Industry Happenings -September 2026

FDA policy, shifting R&D priorities, and heightened oversight of overseas trials are shaping the future of drug development. Don’t miss the latest in BioPharma! Source: PharmaVoice The upcoming reauthorization of the Prescription Drug User Fee Act (PDUFA) could create an opening for Congress to streamline U.S. clinical trials as competition Read more

By Jason Shaneyfelt, ago
Story 2

Industry Insights – August 2026

Stay in tune with the growing changes in drug access and regulatory transparency, including rising insurance denials for brand-name medications and FDA updates around rejection letters and advisory committees. Read on for a closer look at developments shaping the biopharma industry. Source: PharmaVoice Insurance denials for brand-name prescription drugs have Read more

By Jason Shaneyfelt, ago
Man in suit holding back dominos

Will Your Launch Strategy Succeed or Fail?

The Challenge: A Faster, More Complex Launch Environment In today’s pharmaceutical market, strong science is the foundation, but it doesn’t always guarantee a successful launch. Many of us have experienced a disappointing launch when everything we anticipated pointed to success. Today, launches are more complex than they were a decade Read more

By Jason Shaneyfelt, ago
Story 2

Industry Insights – June 2026

From evolving China deal dynamics and prolonged job searches to the growing push for AI-driven drug repurposing, explore how shifts in BioPharma are redefining innovation, hiring, and strategy across the sector. Don’t miss the latest: Source: PharmaVoice The FDA is ramping up efforts to identify new uses for existing drugs, Read more

By Jason Shaneyfelt, ago
FDA Commissioner Marty Makary, M.D.

Industry Insights – May 2026

Biosimilars are gaining U.S. momentum even as patent thickets keep triggering legal fights, small biotechs are feeling the pressure of the FDA’s faster-moving approval environment, and the agency is testing real-time clinical trial review with big-name drugmakers already on board. It’s a fast-changing drug-development landscape worth watching. Don’t miss the Read more

By Jason Shaneyfelt, ago